Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Omeros revenue
Omeros's revenue is $29.9 million.
What is Omeros's revenue?
- Omeros's revenue growth from 2008 to 2018 is 2,452.82%.
- Omeros has 265 employees, and the revenue per employee ratio is $112,709.
- Omeros's peak quarterly revenue was $29.9M in 2019(q3).
- Omeros peak revenue was $64.8M in 2017.
- Omeros annual revenue for 2017 was 64.8M, 55.77% growth from 2016.
- Omeros annual revenue for 2018 was 29.9M, -53.93% growth from 2017.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Omeros historical revenue
Omeros's peak revenue was $64.8M in 2017. The peak quarterly revenue was $29.9M in 2019(q3).
Omeros's revenue increased from $1.2m in 2008 to $29.9M currently. That's a 2,452.82% change in annual revenue.
Omeros annual revenue
Omeros annual revenue over time
| Fiscal year / year | Omeros revenue |
|---|---|
| 2009 | $1.4M |
| 2010 | $2.1M |
| 2011 | $4.5M |
| 2012 | $6.0M |
| 2013 | $1.6M |
| 2014 | $539,000 |
| 2015 | $13.5M |
| 2016 | $41.6M |
| 2017 | $64.8M |
| 2018 | $29.9M |
How accurately did Omeros' revenue projections match actual performance?
Omeros annual growth
Omeros saw the greatest revenue growth in 2015, when revenue increased by 2,406.31%.
Omeros had the lowest revenue growth in 2013, when revenue changed by -73.43%.
Omeros annual growth rate over time
| Year | Omeros growth |
|---|---|
| 2009 | 23%↑ |
| 2010 | 46%↑ |
| 2011 | 115%↑ |
| 2012 | 33%↑ |
| 2013 | -73%↓ |
| 2014 | -66%↓ |
| 2015 | 2406%↑ |
| 2016 | 208%↑ |
| 2017 | 56%↑ |
| 2018 | -54%↓ |
Omeros quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Omeros quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | - | - | $442,000 | $434,000 |
| 2010 | $378,000 | $497,000 | $254,000 | $976,000 |
| 2011 | $1.2M | $1.2M | $987,000 | $1.1M |
| 2012 | $1.5M | $1.5M | $1.4M | $1.6M |
| 2013 | $1.1M | $140,000 | $196,000 | $169,000 |
| 2014 | $100,000 | $45,000 | $214,000 | $180,000 |
| 2015 | $388,000 | $3.2M | $3.3M | $6.7M |
| 2016 | $7.4M | $10.0M | $11.3M | $12.9M |
| 2017 | $12.3M | $17.2M | $21.7M | $13.8M |
| 2018 | $1.6M | $1.7M | $4.6M | $22.0M |
| 2020 | $23.5M | $13.5M | $26.1M | ($63.2M) |
Omeros jobs nearby
Do you work at Omeros?
Did Omeros meet its revenue projections?
Omeros financial information
| CEO | Gregory A. Demopulos |
| Industry | Software & Services |
| Company Type | Public |
| Employees Number | 265 |
| Date Founded | 1994 |
| Headquarters | Seattle, Washington |
| Number of Locations | 1 |
| Revenue | $29.9M |
| Net Income | $47,417,000 |
| Gross Proft | $29.4M (2018) |
| PE Ratio | -5.01 |
| Tax Rate | 0.1% |
| Market Capitalization | $786.1M |
| Total Assets | $590,969,000 |
| Ticker | OMER |
Omeros jobs you might like
Omeros financing
Omeros received early financing of $9.0M on 2007-01-11.
| Series | Round size | Date |
|---|---|---|
| Private Equity | $9M | 01/2007 |
| Series E | $63M | 02/2007 |
| Grant | $465K | 01/2009 |
| Grant | $3.1M | 01/2009 |
| Post Ipo Equity | $40M | 07/2010 |
| Post Ipo Equity | $20M | 10/2010 |
| Grant | $5M | 10/2010 |
| Grant | $1.7M | 11/2010 |
| Grant | $1M | 02/2012 |
| Post Ipo Equity | $34.5M | 07/2012 |
| Grant | $700K | 09/2012 |
| Post Ipo Debt | $32M | 03/2014 |
| Post Ipo Equity | $37.8M | 03/2014 |
| Post Ipo Equity | $84M | 01/2015 |
| Post Ipo Debt | $70M | 01/2016 |
| Post Ipo Debt | $20M | 05/2016 |
| Post Ipo Equity | $40M | 08/2016 |
| Post Ipo Debt | $125M | 11/2016 |
| Post Ipo Equity | $68M | 08/2017 |
| Post Ipo Debt | $210M | 11/2018 |
| Post Ipo Equity | $100M | 08/2020 |
Omeros investors
| Investors | Security type |
|---|---|
| Stanley Medical Research Institute | Private Equity |
| Novartis Venture Fund | Series E |
| Aravis SA | Series E |
| The Grosvenor Funds | Series E |
| Stanley Medical Research Institute | Series E |
| Southern Cross Venture Partners | Series E |
| ARCH Venture Partners | Series E |
| Washington Research Foundation | Series E |
| WRF Capital | Series E |
| Trevi Health Ventures | Series E |
| Michael J. Fox Foundation for Parkinson s Research | Grant |
| Stanley Medical Research Institute | Grant |
| Azimuth Opportunity | Post Ipo Equity |
| Vulcan Capital | Post Ipo Equity |
| Life Sciences Discovery Fund | Grant |
| National Institute on Drug Abuse (NIDA) | Grant |
| National Institute of Mental Health (NIMH) | Grant |
| Oxford Finance LLC | Post Ipo Debt |
| MidCap Financial | Post Ipo Debt |
| Oxford Finance LLC | Post Ipo Debt |
| EAST WEST BANCORP INC | Post Ipo Debt |
| Oxford Finance LLC | Post Ipo Debt |
| EAST WEST BANCORP INC | Post Ipo Debt |
| CRG LP | Post Ipo Debt |
Omeros competitors
Omeros's top competitor, Gilead Sciences, earned an annual revenue of $28.8B.
Omeros's smallest competitor is Synlogic with revenue of $8.0K last year.
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Omeros highest paying jobs
Zippia gives an in-depth look into the details of Omeros, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Omeros. The employee data is based on information from people who have self-reported their past or current employments at Omeros. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Omeros. The data presented on this page does not represent the view of Omeros and its employees or that of Zippia.
Omeros may also be known as or be related to OMEROS CORP, Omeros, Omeros Corp. and Omeros Corporation.